| Dr Sheila Louise Raumer, MD | |
|
130 Bando Court, Alamo, CA 94507 | |
| (925) 930-3110 | |
| (925) 946-1797 |
| Full Name | Dr Sheila Louise Raumer |
|---|---|
| Gender | Female |
| Speciality | Family Medicine - Geriatric Medicine |
| Location | 130 Bando Court, Alamo, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477530988 | NPI | - | NPPES |
| 00A408880 | Medicaid | CA | |
| 623585 | Other | TRIGON |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QG0300X | Family Medicine - Geriatric Medicine | A40888 (California) | Primary |
| Entity Name | La Clinica De La Raza Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144336181 PECOS PAC ID: 1557258282 Enrollment ID: O20040227001016 |
News Archive
Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.
In efforts that may improve diagnoses of many eye diseases, researchers will introduce a new type of laser for providing high-resolution 3-D images of the retina, the part of the eye that converts light to electrical signals that travel to the brain.
Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.
In a White Paper published last year the Government asked the Human Genetics Commission and the National Screening Committee to consider the case for screening every baby at birth and storing their genetic profile for future use.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sheila Louise Raumer, MD 130 Bando Court, Alamo, CA 94507 Ph: (925) 930-3110 | Dr Sheila Louise Raumer, MD 130 Bando Court, Alamo, CA 94507 Ph: (925) 930-3110 |
News Archive
Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.
In efforts that may improve diagnoses of many eye diseases, researchers will introduce a new type of laser for providing high-resolution 3-D images of the retina, the part of the eye that converts light to electrical signals that travel to the brain.
Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.
In a White Paper published last year the Government asked the Human Genetics Commission and the National Screening Committee to consider the case for screening every baby at birth and storing their genetic profile for future use.
› Verified 9 days ago